Objective: Primary cutaneous marginal zone lymphoma (PCMZL) represents a B-cell lymphoma which presents with papules, plaques or nodes. The presence of a monotypical light chain B cell population supports the diagnosis of PCMZL. We describe a case of PCMZL which showed different light chain restriction in two heterochronous lesions. Method: Α 50 year-old male patient presented in 2004 with a cutaneous nodule in the anterior surface of the tibia, which was totally excised. The patient did not show other lesions since 2011, when a new cutaneous nodule located in the right ankle, was appeared. Immunohistochemical analysis was performed in both biopsies. Results: Histological and immunohistochemical findings of both biopsies were consistent with marginal zone lymphoma of the skin with lambda light chain restriction in the biopsy of the first lesion and kappa light chain restriction in the biopsy of the second lesion. Blood laboratory studies, chest and abdominal computerized tomography scans revealed no evidence of systemic involvement by lymphoma. Conclusion: The finding of both kappa and lamda light chain restricted B cell populations in PCMZL is unusual. The monoclonal light chain switching in PCMZL is rare and its pathogenesis is discussed. Objective: Microvessel density (MVD) has prognostic significance in some malignancies. Little information exists about angiogenesis in mantle cell lymphoma (MCL), although antiangiogenic drugs are used experimentally. Prognostic factors of MCL are needed as outcome and therapy are heterogeneous and often unsatisfactory. The aim is to assess MVD in MCL and to evaluate its prognostic significance. Method: 177 MCL specimens (FFPE) were examined by immunohistochemistry with anti-CD34 antibody. MVD was quantified using systematic uniform random sampling and unbiased counting frames. Clinical data were analyzed in Kaplan-Meier survival curves and log-rank test. Results: Median survival (MS) of all patients was 46 months, median progression-free survival (MPFS) 22 months. Mean MVD was 172,7 microvessels/mm2, median 158,2/mm2. Dividing cases into quartiles: <117,4/mm2, <158,2/mm2, <206,6/mm2 and ≥206,6/mm2 (43, 44, 45, 45 cases), MS and MPFS did not differ statistically significantly between these groups (P=0,307; similar for therapy groups). Visible differences are only between the fourth quartile and the rest: Objective: Plasmablastic lymphoma (PBL) is a rare aggressive subtype of diffuse large-B-cell lymphoma which occurs primarily in the oral cavity of HIV-positive patients. It is extremely rare in immunocompetent patients. Method: A total of 5 cases of PB were retrospectively analyzed. All cases had tissue available for immunohistochemistry and in situ hybridization. Results: The age range of the 5 patients was 35-81 years (median 68) and all were men. Three patients were HIV negative. HIV + patients: tumors involved the oral cavity (n =1), and small intestine (n=1). HIV-patients: tumors were located in bone marrow (n=1) and lymph nodes (n=2). All tumors were composed of monomorphic plasmablastic cells. Tumors were negative for CD45 and CD20, while they showed diffuse positivity for CD138, CD38, MUM1 and EMA. By ISH, monoclonal light chain restriction was detected. EBV (EBER) was positive in all cases. The median overall survival was 21,4 months regardless of the intensity of chemotherapy. Only one patient is alive 1 month after diagnosis. Conclusion: PBL may appear in non immunocompromised patients and other locations than oral cavity. Any patient diagnosed with PBL should be tested for HIV. Patients who had HIV-negative PBL have lower rates of oral involvement.